Invivogen
Menu

CD40L Reporter HEK 293 Cells

Product Unit size Cat. code Docs. Qty. Price

HEK-Blue™ CD40L cells

Human CD40L SEAP Reporter Cells

Show product

3-7 x 10e6 cells

hkb-cd40
+-
$1,457

HEK-Blue™ CD40L vial

Additional cell vial

Show product

3-7 x 10e6 cells

hkb-cd40-av
+-

Notification:  Reference #hkb-cd40-av can only be ordered together with reference #hkb-cd40.

CD40L Reporter Cells

HEK-Blue™ CD40L Cells signaling pathway
HEK-Blue™ CD40L Cells signaling pathway

HEK-Blue™ CD40L cells were engineered from the human embryonic kidney HEK 293 cell line to detect bioactive CD40 ligand (CD40L) by monitoring the activation of the NF-κB pathway. CD40L is a protein that is primarily expressed on activated T cells and is a member of the tumor necrosis factor superfamily. Of note, CD40L, together with its receptor CD40, plays a pivotal role in cellular and humoral immunity [1-3].

More details More details

 

Cell line description:

HEK-Blue™ CD40L cells were generated by stable expression of the gene encoding for human CD40 (aka Bp50) and an NF-κB-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. The binding of CD40L to its receptor triggers a signaling cascade leading to the activation of NF-κB and the subsequent production of SEAP. This can be readily assessed in the supernatant using QUANTI-Blue™ Solution, a SEAP detection reagent.

HEK-Blue™ CD40L cells detect human and murine CD40L (see figures). Of note, HEK293 cells endogenously express the receptors for the cytokines IL-1β and TNF-α which share a common signaling pathway with CD40L. Consequently, HEK-Blue™ CD40L cells also respond to IL-1β and TNF-α (see figures). However, the IL-1β- and TNF-α-mediated SEAP production can be blocked using neutralizing antibodies, such as anti-hIL-1β-IgG and anti-hTNF-α-IgA2 respectively.

Key features:

  • Fully functional CD40L signaling pathway
  • Readily assessable NF-κB-inducible SEAP reporter activity

Applications:

  • Detection of human and murine CD40L
  • Screening of anti-CD40 and anti-CD40L antibodies

 

References:

1. Karnell J.L. et al., 2019. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 141:92-103.
2. Laman J.D. et al., 2017. Functions of CD40 and Its Ligand, gp39 (CD40L). Crit Rev Immunol. 37(2-6):371-420.
3. Elgueta R. et al., 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152–172.

Figures

Dose-response of HEK-Blue™ CD40L cells to recombinant CD40L
Dose-response of HEK-Blue™ CD40L cells to recombinant CD40L

Dose-response of HEK-Blue™ CD40L cells to recombinant CD40L. Cells were stimulated with increasing concentrations of recombinant human (h)CD40L. After overnight incubation, the response was determined using QUANTI-Blue™, a SEAP detection reagent. The optical density (OD) at 650 nm is shown as mean ± SEM.

HEK-Blue™ CD40L specificity
HEK-Blue™ CD40L specificity

Response of HEK-Blue™ CD40L cells to a panel of cytokines. Cells were stimulated with various human recombinant cytokines: hIFN-α2b or hIFN-β-1a (1000 U/ml), hIFN-γ (1 µg/ml), hIL-1β (1 ng/ml), hIL-4 (100 ng/ml), hIL-6 (100 ng/ml), hIL-13 (100 ng/ml), hIL-18 (100 ng/ml), hTNF-α (1 ng/ml), hTGF-b1 (100 ng/ml), hCD40L (100 ng/ml), and mCD40L (100 ng/ml). After overnight incubation, SEAP activity was assessed using QUANTI-Blue™. The OD at 650 nm is shown as mean ± SEM.

Dose-dependent inhibition using Anti-hCD40L-IgG mAb
Dose-dependent inhibition using Anti-hCD40L-IgG mAb

Dose-dependent inhibition of HEK-Blue™ CD40L cell response using Anti-hCD40L-IgG mAb. A serial dilution of Anti-hCD40L-hIgG monoclonal antibody (mAb) was incubated with 100 ng/ml of recombinant human CD40L for 30 minutes prior to the addition of the HEK-Blue™ CD40L cells. After overnight incubation, the SEAP response was determined using QUANTI-Blue™, a SEAP detection reagent. Data are presented as percentage of neutralization (mean ± SEM).

Back to the top

Specifications

Antibiotic resistance: Blasticidin, Zeocin®

Growth medium: DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 10% (v/v)  heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml Normocin™

Guaranteed mycoplasma-free

Specification: human and murine CD40L

Detection range:

  • 3 ng - 1 μg/ml for human CD40L
  • 3  ng - 1 μg/ml for murine CD40L

 

This product is covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

  • 1 vial containing 3-7 x 106 cells
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 ml of Zeocin® (100 mg/ml)
  • 1 ml Normocin™ (50 mg/ml)
  • 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)

Dry Ice Shipped on dry ice (Europe, USA, Canada and some areas in Asia)

Back to the top

Details

CD40 Ligand (CD40L), also known as CD154, TRAP, or gp39, is a type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) family. It is mainly expressed in CD4+-T cells and interacts with CD40 on antigen-presenting cells to regulate both humoral and cellular immune responses [1-3].

The CD40 cytoplasmic domain binds directly to several TNF receptor-associated factors (TRAFs), and this interaction is thought to initiate CD40 signaling. CD40-mediated signaling results in NF-κB, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) activation. CD40L-CD40 interactions are thought to play an important role in the pathogenesis of many diseases [4, 5].

 

1. Karnell J.L. et al., 2019. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 141:92-103.
2. Laman J.D. et al., 2017. Functions of CD40 and Its Ligand, gp39 (CD40L). Crit Rev Immunol. 37(2-6):371-420.
3. Elgueta R. et al., 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152–172.
4. Seijkens T. et al., 2013. CD40–CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diabetes and Vascular Disease Research. 10: 115 - 122.
5. Daoussis D. et al., 2004. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol. 11(4):635-41.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

Customer Service
& Technical Support
Shopping cart is empty